Natco Pharma plans rights issue
Natco Pharma (NATCOPHARM) said it has taken up rights issue. The company is valued at about ₹14,050 crore.
What happened
Natco Pharma (NATCOPHARM) told the exchanges on 22 October 2026 at 01:25 PM that it has taken up rights issue.
Company snapshot
Natco Pharma is a small-cap company in the Healthcare sector, with a market value of about ₹14,050 crore.
The stock last traded at ₹784.5, against a 52-week range of ₹773.6–₹1,226.8 (36.1% below the high).
Before this filing the shares had moved −3.6% over the month and −16.0% over three months. Average daily turnover over the last 20 sessions was about ₹39.73 crore.
Promoters held 49.42% at the end of Q1 FY27. Foreign institutions owned 16.99% and domestic institutions 5.62%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,329 | 480.7 | 26.84 |
| Q2 FY26 | 1,363 | 518.4 | 28.94 |
| Q3 FY26 | 647 | 151.5 | 8.46 |
| Q4 FY26 | 739 | 267.9 | 14.96 |
| Q1 FY27 | 735 | 206.5 | 11.53 |
What history shows
BCEIE's records show 6 previous fund raising filings from the company since May 2026.
After those filings, the stock fell 0.6% on average the next trading day and was down 0.5% on average after five days (6 filings with price data).
Across 24 similar disclosures by other Healthcare companies, shares moved +1.3% on average the next day and +1.2% over five days; 63% of them rose the next day.
Market-wide, 1,623 fund raising filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 48% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 28 Sept 2026 | Outcome of Fund Raising Committee Meeting approving the Letter of… | −0.1% | — |
| 25 Sept 2026 | Record date for the purpose of Rights is 01-Oct-2026. | −1.6% | −1.6% |
| 25 Sept 2026 | Issue of Securities on Rights Basis | −1.6% | −1.6% |
| 25 Sept 2026 | Board of Directors at its meeting held on September 25, 2026, has… | −1.6% | −1.6% |
| 21 Sept 2026 | 'Intimation regarding receipt of In-Principle Approval for the… | +2.6% | +3.3% |
What to watch
- How the money raised is used and, for equity instruments, the dilution for existing shareholders.
In the news
Recent coverage elsewhere (links open the original publisher):
- Natco Pharma Ltd. Rights Issue: Price, Record Date, Entitlement Ratio And Key Details
- Natco Pharma launches generic cancer drug Carboplatin in US
- Natco Pharma Ltd. 52 Week Low Streak On Weak Share Price
- NATCO Pharma Launches Generic Carboplatin Injection in US
- NATCO Pharma subsidiary launches Carboplatin in US market to address shortages
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.